Meriofert (Follicle-Stimulating Hormone, Luteinising Hormone)

Follicle‑stimulating hormone binds to receptors on ovarian granulosa cells, promoting follicular growth and estrogen synthesis. Luteinising hormone binds to receptors on theca and luteal cells, stimulating androgen production and triggering the LH surge that leads to final oocyte maturation and ovulation. Together they replicate the natural pituitary signals that regulate the menstrual cycle.

The dose of Meriofert is individualized by the prescribing physician based on the patient’s ovarian response, hormone levels, and specific treatment protocol. Clinicians adjust the amount and frequency of injections using ultrasound monitoring and serum estradiol measurements to achieve optimal follicular development while minimizing the risk of ovarian hyperstimulation.

Meriofert is intended for use before conception to induce ovulation and is not recommended for administration during an established pregnancy. Limited data exist regarding its excretion in breast milk, and the product is generally avoided while breastfeeding unless a qualified healthcare professional determines that the potential benefits outweigh any possible risks.

To place an order, submit an enquiry on the Meriofert product page at gnhindia.com, providing the required quantity and institutional credentials. GNH India works with hospitals, pharmacies and procurement teams worldwide, confirming trade or institutional verification before responding with pricing, availability, shipping details—including cold‑chain logistics if needed—and the necessary import documentation.

Compared with recombinant FSH products, Meriofert contains both FSH and LH in a single formulation, which can simplify dosing for patients requiring both hormones. While recombinant preparations may offer higher purity, urinary‑derived gonadotropins like Meriofert have a long safety record. Choice of therapy depends on clinical protocol, patient response, and cost considerations.

Meriofert should be stored at 2‑8 °C (36‑46 °F) in a refrigerator. The vial must be kept in its original packaging to protect it from light, and it should not be frozen or shaken. Once removed from refrigeration, the product may be used for a limited period as indicated in the prescribing information, after which any remaining solution should be discarded.

Meriofert is supplied as a sterile injectable solution for intramuscular or subcutaneous injection. Healthcare professionals draw the required dose into a sterile syringe and administer it according to the prescribed schedule, typically once daily or as directed by the treatment protocol. Proper aseptic technique and correct injection site selection are essential to minimize local reactions and ensure accurate dosing.

The most serious risks include ovarian hyperstimulation syndrome (OHSS), which can cause abdominal distension, fluid accumulation, and, in severe cases, thromboembolic events; multiple pregnancy, which increases obstetric complications; and rare allergic reactions such as anaphylaxis. Patients should be closely monitored with ultrasound and hormone assays, and treatment should be adjusted or discontinued if signs of severe OHSS or hypersensitivity appear.

Meriofert is contraindicated in women who are currently pregnant, have known hypersensitivity to any component of the product, or have active ovarian cysts, uncontrolled thyroid disease, or severe uncontrolled endocrine disorders. Caution is also advised for patients with a history of thromboembolic disease or severe ovarian hyperstimulation. The prescribing clinician must evaluate each individual’s medical history before initiating therapy.